Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Vanda ( (VNDA) ) is now available.
On January 25, 2025, Vanda Pharmaceuticals Inc. announced on the social media platform X the filing of a new drug application for tradipitant, intended for treating motion sickness. The announcement highlights the drug’s potential significance, drawing historical parallels to the seasickness challenges faced during WWII and suggesting the condition’s broader impact beyond daily discomfort, potentially affecting national security.
More about Vanda
Vanda Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing and commercializing treatments for central nervous system disorders.
YTD Price Performance: -8.71%
Average Trading Volume: 637,692
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $256.6M
See more data about VNDA stock on TipRanks’ Stock Analysis page.
